Emcure, Intas Indian IPOs to test pharma investor appetite
This article was originally published in Scrip
Two of India's top 15 drug companies by market share - Emcure Pharmaceuticals and Intas Pharmaceuticals - have filed for initial public offerings amid some general concern that the pharmaceutical sector may no longer be a blind defensive play. But industry experts nevertheless believe that investor enthusiasm is unlikely to be dimmed for the proposed offerings, which are also expected to facilitate the part exits of leading private equity firms.
You may also be interested in...
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.